Researchers have discovered an immune cell with the attributes of both B cells and T cells, which is present in increased frequency in some people with type 1 diabetes and capable of activating insulin-specific T-helper cells.
Diabetologist Sanjay Kalra puts the CAROLINA trial into historical context and considers the present-day implications for the use of DPP-4 inhibitors and sulfonylureas.
WATCH | Nephrologist Katherine Tuttle and Primary Care Physician Jay Shubrook discuss referrals to nephrology for patients with comorbid diabetes and kidney disease (8:38).
Of the immunotherapies tested to date, teplizumab and low-dose antithymocyte globulin are the most promising for slowing the decline in C-peptide in people with newly diagnosed type 1 diabetes, researchers report.
Detailed analysis of renal outcomes in the DECLARE-TIMI 58 trial confirms that treatment with the sodium-glucose cotransporter 2 inhibitor dapagliflozin is renoprotective in patients with type 2 diabetes and preserved kidney function.
Canagliflozin reduces the risk for major cardiovascular events and kidney failure versus placebo in patients with type 2 diabetes and chronic kidney disease with and without a known history of cardiovascular disease, CREDENCE study data show.
Secondary data from the CARMELINA trial, presented at the 79th ADA Scientific Sessions in San Francisco, California, USA, confirm the positive primary cardiovascular and renal safety findings, this time in particularly high-risk patients.
The PIONEER 6 trial demonstrates the noninferior cardiovascular safety profile of oral semaglutide compared with placebo, but fails to demonstrate superiority, despite an overall positive trend and significance for cardiovascular death.
The dipeptidyl peptidase-4 inhibitor linagliptin and the sulfonylurea glimepiride have similar cardiovascular safety profiles, show the results of the CAROLINA trial.
Diabetologist Sanjay Kalra puts the CAROLINA trial into historical context and considers the present-day implications for the use of DPP-4 inhibitors and sulfonylureas.
Fournier gangrene remains very rare, but is more common in people using SGLT2 inhibitors compared with other diabetes medications and has severe consequences, shows research.
Findings from the GRAVITAS trial indicate that use of the GLP-1 receptor agonist liraglutide alongside a diet and physical activity intervention may improve glycemic control among people with persistent or recurrent type 2 diabetes after bariatric surgery.
Editorial Board member Lori Berard discusses how the ambulatory glucose profile is quietly revolutionizing the analysis of blood glucose and glycemic control for patients and practitioners.
Oral semaglutide offers greater efficacy for glucose control and weight loss when compared with sitagliptin for people with type 2 diabetes, although with more adverse events at the highest dose, show the PIONEER 3 findings.
